Cost Insights: Breaking Down Viatris Inc. and Ligand Pharmaceuticals Incorporated's Expenses

Cost Insights: Viatris Inc. vs. Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue for Viatris Inc. and Ligand Pharmaceuticals from 2014 to 2023. Over this period, Viatris Inc. consistently reported higher costs, peaking in 2021 with a staggering 12.3 billion dollars, reflecting its expansive operations. In contrast, Ligand Pharmaceuticals, a smaller entity, saw its cost of revenue rise significantly in 2021, reaching 62 million dollars, a tenfold increase from 2014. This disparity highlights the differing scales and strategies of these companies. Viatris's costs are approximately 400 times greater than Ligand's, underscoring its larger market footprint. As the industry faces challenges like regulatory changes and market competition, these insights provide a window into how these companies manage their financial health.